Physalemin (BioDeep_00000182407)

   

human metabolite blood metabolite


代谢物信息卡片


4-(2-{[1-({5-amino-1-[(1-{[1-({[(1-{[1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]pentyl}-C-hydroxycarbonimidoyl)-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-[(1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}propylidene)amino]-4-oxobutanoic acid

化学式: C58H84N14O16S (1264.5910144000002)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C4CCC(=O)N4
InChI: InChI=1S/C58H84N14O16S/c1-31(2)25-39(54(84)66-36(49(61)79)21-24-89-4)65-47(76)30-62-51(81)40(27-34-15-17-35(73)18-16-34)68-55(85)41(26-33-11-6-5-7-12-33)69-53(83)37(13-8-9-22-59)67-56(86)42(28-45(60)74)70-57(87)44-14-10-23-72(44)58(88)43(29-48(77)78)71-50(80)32(3)63-52(82)38-19-20-46(75)64-38/h5-7,11-12,15-18,31-32,36-44,73H,8-10,13-14,19-30,59H2,1-4H3,(H2,60,74)(H2,61,79)(H,62,81)(H,63,82)(H,64,75)(H,65,76)(H,66,84)(H,67,86)(H,68,85)(H,69,83)(H,70,87)(H,71,80)(H,77,78)

描述信息

同义名列表

6 个代谢物同义名

4-(2-{[1-({5-amino-1-[(1-{[1-({[(1-{[1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]pentyl}-C-hydroxycarbonimidoyl)-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-[(1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}propylidene)amino]-4-oxobutanoic acid; 4-(2-{[1-({5-amino-1-[(1-{[1-({[(1-{[1-(C-hydroxycarbonimidoyl)-3-(methylsulphanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]pentyl}-C-hydroxycarbonimidoyl)-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-[(1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}propylidene)amino]-4-oxobutanoate; 4-(2-{[1-({5-amino-1-[(1-{[1-({[(1-{[1-(C-hydroxycarbonimidoyl)-3-(methylsulfanyl)propyl]-C-hydroxycarbonimidoyl}-3-methylbutyl)-C-hydroxycarbonimidoyl]methyl}-C-hydroxycarbonimidoyl)-2-(4-hydroxyphenyl)ethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]pentyl}-C-hydroxycarbonimidoyl)-2-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}pyrrolidin-1-yl)-3-[(1-hydroxy-2-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}propylidene)amino]-4-oxobutanoate; 4-(2-{[1-({5-amino-1-[(1-{[1-({[(1-{[1-carbamoyl-3-(methylsulfanyl)propyl]carbamoyl}-3-methylbutyl)carbamoyl]methyl}carbamoyl)-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-phenylethyl)carbamoyl]pentyl}carbamoyl)-2-carbamoylethyl]carbamoyl}pyrrolidin-1-yl)-4-oxo-3-{2-[(5-oxopyrrolidin-2-yl)formamido]propanamido}butanoic acid; physalaemin; Physalemin



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Hui-ping Zhang, Cui-ling Li, Peng Lu, Jia-cui Zheng, Li-li Yu, Wei-min Yang, Fei Xiong, Xiao-yong Zeng. The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats. World journal of urology. 2014 Feb; 32(1):91-7. doi: 10.1007/s00345-013-1098-z. [PMID: 23666265]
  • Christy Rani R Grace, Sudha Mahajan Cowsik. Solution conformation of non-mammalian tachykinin physalaemin in lipid micelles by nuclear magnetic resonance. Biopolymers. 2011; 96(3):252-9. doi: 10.1002/bip.21519. [PMID: 20632396]
  • Yoichi Chida, Nobuyuki Sudo, Junko Sonoda, Tetsuya Hiramoto, Chiharu Kubo. Early-life psychological stress exacerbates adult mouse asthma via the hypothalamus-pituitary-adrenal axis. American journal of respiratory and critical care medicine. 2007 Feb; 175(4):316-22. doi: 10.1164/rccm.200607-898oc. [PMID: 17110645]
  • M Abdel-Gawad, S B Dion, M M Elhilali. Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. The Journal of urology. 2001 May; 165(5):1739-44. doi: . [PMID: 11342967]
  • R V Schoborg, D B Hoover, J D Tompkins, J C Hancock. Increased ganglionic responses to substance P in hypertensive rats due to upregulation of NK(1) receptors. American journal of physiology. Regulatory, integrative and comparative physiology. 2000 Nov; 279(5):R1685-94. doi: 10.1152/ajpregu.2000.279.5.r1685. [PMID: 11049850]
  • C T O'Shaughnessy, H E Connor. Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater. European journal of pharmacology. 1994 Sep; 263(1-2):193-8. doi: 10.1016/0014-2999(94)90541-x. [PMID: 7821352]
  • Y Chen, D B Hoover. Pharmacological characterization of the pressor response to tachykinins in isolated perfused rat kidney. The Journal of pharmacology and experimental therapeutics. 1993 Dec; 267(3):1176-80. doi: NULL. [PMID: 7505328]
  • X Zhao, J A Valantas, S Vyas, L K Duffy. Comparative toxicity of amyloid beta-peptide in neuroblastoma cell lines: effects of albumin and physalaemin. Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology. 1993 Sep; 106(1):165-70. doi: 10.1016/0742-8413(93)90268-p. [PMID: 7903610]
  • C J Fowler, T Martinsson, G Brännström. 'Specific' binding of [3H]-[Sar9,Met(O2)11]-substance P to tissue culture plates is found when substance P is used to define non-specific binding. Methods and findings in experimental and clinical pharmacology. 1993 Jul; 15(6):337-43. doi: NULL. [PMID: 7694018]
  • C T O'Shaughnessy, H E Connor. Neurokinin NK1 receptors mediate plasma protein extravasation in guinea-pig dura. European journal of pharmacology. 1993 May; 236(2):319-21. doi: 10.1016/0014-2999(93)90605-h. [PMID: 7686494]
  • A Ia Avanov. [Conformational analysis of tachykinins. I. N-terminal fragments of substance P, physalemin, hylambatin, and uperolein]. Bioorganicheskaia khimiia. 1991 May; 17(5):637-46. doi: ". [PMID: 1722675]
  • L Abelli, V Somma, C A Maggi, D Regoli, M Astolfi, M Parlani, P Rovero, B Conte, A Meli. Effects of tachykinins and selective tachykinin receptor agonists on vascular permeability in the rat lower urinary tract: evidence for the involvement of NK-1 receptors. Journal of autonomic pharmacology. 1989 Aug; 9(4):253-63. doi: 10.1111/j.1474-8673.1989.tb00216.x. [PMID: 2475507]
  • P V Andrews, R D Helme, K L Thomas. NK-1 receptor mediation of neurogenic plasma extravasation in rat skin. British journal of pharmacology. 1989 Aug; 97(4):1232-8. doi: 10.1111/j.1476-5381.1989.tb12583.x. [PMID: 2477105]
  • G Bepler, D N Carney, A F Gazdar, J D Minna. In vitro growth inhibition of human small cell lung cancer by physalaemin. Cancer research. 1987 May; 47(9):2371-5. doi: NULL. [PMID: 2436762]
  • M Maruyama. Selective solubilization of physalaemin-type substance P binding sites from rat brain membranes by glycodeoxycholate and NaCl. Brain research. 1986 Apr; 370(1):186-90. doi: 10.1016/0006-8993(86)91122-4. [PMID: 3011190]
  • T Mitsuma, T Nogimori, M Chaya. Physalaemin inhibits thyrotropin secretion in rats. Experimental and clinical endocrinology. 1985 Jun; 85(3):319-25. doi: 10.1055/s-0029-1210457. [PMID: 3930270]
  • X Hua, J M Lundberg, E Theodorsson-Norheim, E Brodin. Comparison of cardiovascular and bronchoconstrictor effects of substance P, substance K and other tachykinins. Naunyn-Schmiedeberg's archives of pharmacology. 1984 Dec; 328(2):196-201. doi: 10.1007/bf00512072. [PMID: 6084817]
  • H G Güllner, V Harris, H Yajima, R H Unger. Hylambatin, a structurally unique tachykinin: effects on insulin and glucagon secretion. Archives internationales de pharmacodynamie et de therapie. 1984 Dec; 272(2):304-9. doi: NULL. [PMID: 6395822]
  • F Cantalamessa, G De Caro, M Massi, M Perfumi. Possible influence of tachykinins on body fluid homeostasis in the rat. Journal de physiologie. 1984; 79(6):524-30. doi: NULL. [PMID: 6085638]
  • J T Fitzsimons, M Massi, S N Thornton. The effects of changes in osmolality and sodium concentration on angiotensin-induced drinking and excretion in the pigeon. The Journal of physiology. 1982 Sep; 330(?):1-15. doi: 10.1113/jphysiol.1982.sp014325. [PMID: 7175737]
  • R T Jensen, J D Gardner. Interaction of physalaemin, substance P, and eledoisin with specific membrane receptors on pancreatic acinar cells. Proceedings of the National Academy of Sciences of the United States of America. 1979 Nov; 76(11):5679-83. doi: 10.1073/pnas.76.11.5679. [PMID: 230488]
  • A R Denniss, J A Young. Modification of salivary duct electrolyte transport in rat and rabbit by physalaemin, VIP, GIP and other enterohormones. Pflugers Archiv : European journal of physiology. 1978 Aug; 376(1):73-80. doi: 10.1007/bf00585250. [PMID: 568244]